One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1182/blood-2015-10-671388
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Dec 24, 2015 |
 Citations: 1 |
Affiliation: Manchester Academic Health Science Centre
In this issue of Blood , [Forero-Torres et al][1][1][2] report encouraging results from a phase 2 study of brentuximab vedotin in the first-line treatment of older patients with Hodgkin lymphoma (HL). This is a population in whom frailty and comorbidity are common and outcomes poor when compared
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
